

09<sup>th</sup> February 2023

To,  
The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street, Mumbai - 400 001.  
Scrip Code - 543308  
ISIN: INE967H01017

Dear Sir,

Sub: Approval of Un-Audited Financial Results for the 3<sup>rd</sup> Quarter and nine months ended 31<sup>st</sup> December 2022

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have approved the Un-Audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the 3<sup>rd</sup> Quarter and nine months ended 31<sup>st</sup> December 2022 which are enclosed to this letter.

The financial results are also available on the website of the Company at [www.kimshospitals.com/Investors/Disclosures](http://www.kimshospitals.com/Investors/Disclosures) under Regulation 46 of SEBI (LODR) Regulations, 2015/ [Financial Information/ Financial Results/FY22-23](http://www.kimshospitals.com/Investors/Disclosures) and also on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively.

The Board Meeting commenced at 02.00 P.M and concluded at..... 6.00 PM

This is for your information and records.

Thanking you,

For Krishna Institute of Medical Sciences Limited



Umashankar Mantha

Company Secretary & Compliance Officer

Encl : As above




**Krishna Institute of Medical Sciences Limited**

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India  
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | [kimshospitals.com](http://kimshospitals.com)  
CIN: L55101TG1973PLC040558

**Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2022**

(Rupees in millions)

	Quarter Ended			Nine months period ended		Year ended
	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>					
(a) Revenue from operations	2,835.13	2,922.08	2,731.93	8,386.71	8,888.80	11,433.76
(b) Other income	71.84	76.34	31.04	185.25	164.59	241.74
<b>Total Income</b>	<b>2,906.97</b>	<b>2,998.42</b>	<b>2,762.97</b>	<b>8,571.96</b>	<b>9,053.39</b>	<b>11,675.50</b>
<b>2</b>	<b>Expenses</b>					
(a) Purchase of medical consumables, drugs and surgical instruments	602.98	564.90	577.75	1,733.74	2,060.72	2,594.21
(b) (Increase) / Decrease in inventories of medical consumables, drugs and surgical instruments	(2.84)	62.81	(2.30)	55.74	(72.77)	(95.14)
(c) Employee benefits expense	450.27	472.00	405.60	1,396.14	1,311.03	1,740.21
(d) Other expenses	885.01	943.81	763.21	2,641.52	2,510.33	3,232.28
(e) Finance cost	2.44	3.27	6.19	9.76	39.43	44.68
(f) Depreciation and amortisation expense	113.48	113.78	114.12	341.38	335.68	449.22
<b>Total Expenses</b>	<b>2,051.34</b>	<b>2,160.57</b>	<b>1,864.57</b>	<b>6,178.28</b>	<b>6,184.42</b>	<b>7,965.46</b>
<b>3</b>	<b>Profit before tax (1-2)</b>					
	<b>855.63</b>	<b>837.85</b>	<b>898.40</b>	<b>2,393.68</b>	<b>2,868.97</b>	<b>3,710.04</b>
<b>4</b>	<b>Tax expense</b>					
(a) Current tax	198.51	232.99	223.77	609.14	731.02	909.27
(b) Deferred tax charge/(credit)	12.45	(7.17)	4.69	6.63	(6.67)	29.73
(c) Adjustment of tax relating to earlier periods/years	-	-	-	-	-	(12.63)
<b>Total tax expenses</b>	<b>210.96</b>	<b>225.82</b>	<b>228.46</b>	<b>615.77</b>	<b>724.35</b>	<b>926.37</b>
<b>5</b>	<b>Profit for the period/year (3-4)</b>					
	<b>644.67</b>	<b>612.03</b>	<b>669.94</b>	<b>1,777.91</b>	<b>2,144.62</b>	<b>2,783.67</b>
<b>6</b>	<b>Other comprehensive income/ (loss)</b>					
Items that will not be reclassified subsequently to statement of profit and loss						
- Re-measurement gain/(loss) on defined benefit plans	3.07	5.49	(4.56)	9.22	(13.67)	2.63
- Income tax effect	(0.77)	(1.38)	1.15	(2.32)	3.44	(0.66)
<b>Other comprehensive income/ (loss), net of tax</b>	<b>2.30</b>	<b>4.11</b>	<b>(3.41)</b>	<b>6.90</b>	<b>(10.23)</b>	<b>1.97</b>
<b>7</b>	<b>Total comprehensive income (5+6)</b>					
	<b>646.97</b>	<b>616.14</b>	<b>666.53</b>	<b>1,784.81</b>	<b>2,134.39</b>	<b>2,785.64</b>
<b>8</b>	<b>Paid up equity share capital (face value of Rs.10 each)</b>					
<b>9</b>	<b>Other Equity</b>					
						800.28
<b>10</b>	<b>Earnings per share (of Rs.10 each) : (not annualised for the quarter ended)</b>					
(a) Basic (Rs.)	8.06	7.65	8.37	22.22	28.32	35.04
(b) Diluted (Rs.)	8.06	7.65	8.37	22.22	28.32	35.04



*[Handwritten signature]*

Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter and nine months period ended 31 December 2022 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 09 February 2023 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 4 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 5 During the previous quarter, the Company acquired 51% of the equity share capital of the SPANV Medisearch Lifesciences Private Limited (SPANV) for a total cash consideration of Rs. 800.03 Mn and SPANV had become a subsidiary. The transaction was accounted in accordance with Ind AS 103 - Business Combinations ("Ind AS 103") and the initial accounting is provisionally determined as at 31 December 2022.
- 6 The previous periods numbers have been regrouped/rearranged wherever necessary to conform the current period presentation.
- 7 The above Unaudited Standalone Financial Results of the Company are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.


Hyderabad  
09 February 2023

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited



A handwritten signature in blue ink, appearing to read "Dr. B Bhaskara Rao".

Dr. B Bhaskara Rao  
Managing Director  
DIN: 00008985




**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 23102328 B65BLB1242


Place: Hyderabad

Date: February 09, 2023



Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months period ended 31 December 2022

		Quarter ended			Nine months period ended		Year ended
		31-Dec-22 (Unaudited)	30-Sep-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Dec-22 (Unaudited)	31-Dec-21 (Unaudited)	31-Mar-22 (Audited)
1	<b>Income</b>						
	(a) Revenue from operations	5,621.62	5,640.72	3,935.68	16,217.49	12,784.87	16,508.25
	(b) Other income	64.51	92.04	23.92	209.89	120.71	202.60
	<b>Total Income</b>	<b>5,686.13</b>	<b>5,732.76</b>	<b>3,959.60</b>	<b>16,427.38</b>	<b>12,905.58</b>	<b>16,710.85</b>
2	<b>Expenses</b>						
	(a) Purchase of medical consumables, drugs and surgical instruments	1,240.58	1,184.65	822.72	3,552.14	2,889.69	3,674.97
	(b) (Increase)/ decrease in inventories of medical consumables, drugs and surgical instruments	(5.49)	68.27	(0.92)	33.55	(89.31)	(123.42)
	(c) Employee benefits expense	871.95	841.59	610.40	2,546.64	1,970.57	2,619.08
	(d) Other expenses	2,002.76	2,021.89	1,205.87	5,677.39	3,991.84	5,179.73
	(e) Finance cost	115.24	78.80	29.65	231.30	121.74	160.33
	(f) Depreciation and amortisation expense	332.92	311.19	188.08	938.29	540.36	726.73
	<b>Total Expenses</b>	<b>4,557.96</b>	<b>4,506.39</b>	<b>2,855.80</b>	<b>12,999.31</b>	<b>9,424.89</b>	<b>12,237.42</b>
3	<b>Profit before share of profit from Joint Venture and tax (1-2)</b>	<b>1,128.17</b>	<b>1,226.37</b>	<b>1,103.80</b>	<b>3,428.07</b>	<b>3,480.69</b>	<b>4,473.43</b>
4	<b>Share of profit from Joint Venture, net of tax</b>	-	-	19.66	-	19.66	95.10
5	<b>Profit before tax and exceptional items (3+4)</b>	<b>1,128.17</b>	<b>1,226.37</b>	<b>1,123.46</b>	<b>3,428.07</b>	<b>3,500.35</b>	<b>4,568.53</b>
6	<b>Exceptional Items</b>	-	148.29	-	148.29	-	-
7	<b>Profit before tax (5+6)</b>	<b>1,128.17</b>	<b>1,374.66</b>	<b>1,123.46</b>	<b>3,576.36</b>	<b>3,500.35</b>	<b>4,568.53</b>
8	<b>Tax expense</b>						
	(a) Current tax	290.03	344.16	277.30	895.43	915.03	1,141.55
	(b) Deferred tax charge/(credit)	25.73	(11.65)	4.29	33.94	(19.39)	1.66
	(c) Adjustment of tax relating to earlier periods/years	(5.86)	(18.53)	-	(24.39)	-	(12.63)
	<b>Total tax expenses (8)</b>	<b>309.90</b>	<b>313.98</b>	<b>281.59</b>	<b>904.98</b>	<b>895.64</b>	<b>1,130.58</b>
9	<b>Profit for the period/year (7-8)</b>	<b>818.27</b>	<b>1,060.68</b>	<b>841.87</b>	<b>2,671.38</b>	<b>2,604.71</b>	<b>3,437.95</b>
	<b>Attributable to:</b>						
	Owners of the company	759.80	971.14	811.75	2,430.50	2,519.97	3,326.83
	Non controlling interests	58.47	89.54	30.12	240.88	84.74	111.10
10	<b>Other comprehensive income/(loss) for the period/year</b>						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement gain/(loss) on defined benefit plans	1.78	2.19	(4.57)	7.61	(16.48)	1.53
	- Income tax effect	(0.57)	(0.49)	1.15	(1.96)	4.21	(0.33)
	<b>Other comprehensive income/(loss), net of tax</b>	<b>1.21</b>	<b>1.70</b>	<b>(3.42)</b>	<b>5.65</b>	<b>(12.27)</b>	<b>1.20</b>
	<b>Attributable to:</b>						
	Owners of the company	1.58	2.58	(3.04)	5.76	(11.60)	1.40
	Non controlling interests	(0.37)	(0.88)	(0.38)	(0.11)	(0.67)	(0.20)
11	<b>Total comprehensive income (9+10)</b>	<b>819.48</b>	<b>1,062.38</b>	<b>838.45</b>	<b>2,677.03</b>	<b>2,592.44</b>	<b>3,439.15</b>
	<b>Owners of the company</b>	<b>761.38</b>	<b>973.72</b>	<b>808.71</b>	<b>2,436.26</b>	<b>2,308.37</b>	<b>3,328.25</b>
	<b>Non controlling interests</b>	<b>58.10</b>	<b>88.66</b>	<b>29.74</b>	<b>240.77</b>	<b>84.07</b>	<b>110.90</b>
	<b>Total comprehensive income</b>	<b>819.48</b>	<b>1,062.38</b>	<b>838.45</b>	<b>2,677.03</b>	<b>2,592.44</b>	<b>3,439.15</b>
12	<b>Paid up equity share capital (face value of Rs.10 each)</b>						800.28
13	<b>Other Equity</b>						13,072.81
14	<b>Earnings per share (of Rs.10 each); (not annualised for the quarter ended)</b>						
	(a) Basic (Rs.)	9.49	12.14	10.14	30.37	33.27	41.88
	(b) Diluted (Rs.)	9.49	12.14	10.14	30.37	33.27	41.88



Handwritten signature


Notes:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31 December 2022 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 09 February 2023 and have been subject to limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 3 The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 4 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 5 During the quarter, the Company has acquired additional stake in 3 of its subsidiaries, 1.92% in Sarvejana Healthcare Private Limited, 4.07% in KIMS Hospital Enterprise Private Limited, 7.79% in Arunodaya Hospital Private Limited.
- 6 During the previous quarter, the Company acquired 51% of the equity share capital of the SPANV Medisearch Lifesciences Private Limited ('SPANV') for a total cash consideration of Rs. 800.03 Mn and SPANV had become a subsidiary. The transaction was accounted in accordance with Ind AS 103 - Business Combinations ("Ind AS 103") and the initial accounting is provisionally determined as at 31 December 2022.
- 7 The previous periods/years numbers have been regrouped/rearranged wherever necessary to conform the current period/year presentation.
- 8 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website [www.kimshospitals.com](http://www.kimshospitals.com) and also on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)), where the shares of the Company are listed.

For and on behalf of the Board  
Krishna Institute of Medical Sciences Limited

  
Dr. B Bhaskara Rao  
Managing Director  
DIN: 00008985

Hyderabad  
Thursday, February 9, 2023



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Krishna Institute of Medical Sciences Limited**

- We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended December 31, 2022 and year to date from April 01, 2022 to December 31, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

- The Statement includes the results of the following entities:

S.no.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital (Bengaluru) Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited *	Subsidiary
11	Rajyalakshmi Healthcare Private Limited *	Subsidiary
12	Suryateja Healthcare Private Limited **	Subsidiary
13	KIMS Manavata Hospitals Private Limited *	Subsidiary
14	Spanv Medisearch Lifesciences Private Limited *	Subsidiary

\* Become Subsidiary during the period from April 01, 2022 to December 31, 2022

\*\* Entity ceased to be Subsidiary from December 01, 2022



# S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of 2 subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil and Rs Nil, total net loss after tax of Rs. 0.86 million and total net profit after tax Rs 0.49 million, total comprehensive loss of Rs. 0.86 million and total comprehensive income of Rs. 0.49 million, for the quarter ended December 31, 2022 and the period ended on that date respectively for the period from April 01, 2022 to December 31, 2022, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our Conclusion on the statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of other auditors.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004



per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 23102328 BLSBLC7775

Place: Hyderabad

Date: February 09, 2023

